Crescent Biopharma (NASDAQ:CBIO) Coverage Initiated by Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Crescent Biopharma (NASDAQ:CBIO) in a research report report published on Monday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $26.00 price objective on the biopharmaceutical company’s stock.

Several other brokerages have also issued reports on CBIO. Wedbush initiated coverage on Crescent Biopharma in a research note on Monday, July 14th. They issued an “outperform” rating and a $27.00 price target on the stock. HC Wainwright initiated coverage on Crescent Biopharma in a research report on Monday, August 11th. They set a “buy” rating and a $25.00 target price on the stock. Stifel Nicolaus initiated coverage on Crescent Biopharma in a research report on Wednesday, June 25th. They set a “buy” rating and a $28.00 target price on the stock. Lifesci Capital raised Crescent Biopharma to a “strong-buy” rating and set a $22.00 target price on the stock in a research report on Wednesday, June 18th. Finally, Wall Street Zen lowered Crescent Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, August 2nd. Two research analysts have rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $25.60.

Crescent Biopharma Stock Down 2.4%

NASDAQ:CBIO opened at $14.70 on Monday. Crescent Biopharma has a 1-year low of $10.83 and a 1-year high of $63.00. The firm has a fifty day moving average price of $13.92. The company has a market capitalization of $287.39 million, a PE ratio of -0.42 and a beta of 1.51.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. BVF Inc. IL bought a new position in shares of Crescent Biopharma during the 2nd quarter worth $22,400,000. Perceptive Advisors LLC bought a new position in shares of Crescent Biopharma during the 2nd quarter worth $7,322,000. Commodore Capital LP bought a new position in shares of Crescent Biopharma during the 2nd quarter worth $7,322,000. Frazier Life Sciences Management L.P. bought a new position in shares of Crescent Biopharma during the 2nd quarter worth $7,322,000. Finally, Soleus Capital Management L.P. bought a new position in shares of Crescent Biopharma during the 2nd quarter worth $6,456,000. Institutional investors own 75.19% of the company’s stock.

Crescent Biopharma Company Profile

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.